Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Business Roundup

June 19, 2006 | A version of this story appeared in Volume 84, Issue 25

Avecia Biotechnology has won a $3.9 million grant from the National Institute of Allergy & Infectious Diseases to develop the next generation of its anthrax vaccine, Thraxine. The goal is to improve the temperature stability of the vaccine.

BOC Edwards and its Taiwanese partner are spending $30 million to add nitrogen capacity and pipelines at Taiwan's Hsinchu Science Park. BOC, which already has nine nitrogen plants in Hsinchu, says the addition will feature its largest semiconductor-grade nitrogen generator.

PharmAthene and SIGA Technologies have agreed to merge to create a biodefense products company. The combined business, which will operate as PharmAthene, says it will target three of the top five biodefense priorities identified under Project BioShield.

BASF has completed the acquisition of Engelhard. As a result, Engelhard is now a wholly owned subsidiary of BASF, and its shares no longer trade on the New York Stock Exchange.

Merck's Gardasil, a recombinant vaccine to prevent cervical cancer, has been approved by FDA. The vaccine, the first of its kind, is designed to prevent cervical cancer caused by human papillomavirus, which causes up to 70% of cervical cancers.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.